Contrast media volume reduction with the DyeVertTM system to prevent acute kidney injury in stable patients undergoing coronary procedures

Abstract

AbstractBackgroundContrast associated acute kidney injury (CA‐AKI) can lead to an increased risk of adverse events. Contrast media (CM) volume reduction has been advocated as a pivotal strategy to prevent CA‐AKI in stable patients undergoing percutaneous coronary procedures.AimsTo compare the effectiveness of CM volume reduction with the DyeVertTM system versus conventional strategy in reducing the risk of CA‐AKI.MethodsWe prospectively collected data from 136 patients with stable coronary artery disease at high risk of CA‐AKI treated with left ventricular end diastolic pressure (LVEDP)‐ guided hydration and undergoing interventions with the use of the DyeVertTM (Osprey Medical Inc.) system. Patients previously enrolled in the LVEDP‐guided hydration arm of the “Renal Insufficiency Following Contrast MEDIA Administration triaL III” (REMEDIAL III) were considered as controls. Propensity score was used to perform 1:1 matching to adjust for major confounders. The primary outcome was the occurrence of CA‐AKI, as defined by an absolute increase of creatinine values ≥0.3 mg/dL at 48 h.ResultsPatients in the DyeVert group were treated with a significant lower CM volume (median: 47.5 vs. 84.0 mL, p < 0.001). The trend in creatinine increase was lower (p = 0.004) and the Δ of creatinine (0−48 h) showed a higher drop (−0.18 vs. −0.10 mg/dL, p = 0.036) in the DyeVert group. The risk of CA‐AKI was significantly lower in DyeVert group compared to control group (5.1% vs. 16.8%; odds ratio 0.27, 95% confidence interval [0.12−0.61]).ConclusionsCM volume reduction with the DyeVertTM system seems to be superior to conventional strategies in reducing the occurrence of CA‐AKI.